Publications by authors named "A N D'Agostino"

Background: Pulmonary hypertension (PH) is a pathophysiological problem that may involve several clinical symptoms and be linked to various respiratory and cardiovascular illnesses. Its diagnosis is made invasively by Right Cardiac Catheterization (RHC), which is difficult to perform routinely. Aim of the current study was to develop a Machine Learning (ML) algorithm based on the analysis of anamnestic data to predict the presence of an invasively measured PH.

View Article and Find Full Text PDF

Background: Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use of antivirals and monoclonal antibodies in this population are scarce.

Research Design And Methods: We performed an observational, prospective study, enrolling immunocompromised outpatients with mild-to-moderate COVID-19, treated with a combination of sotrovimab plus one antiviral (remdesivir or nirmatrelvir/ritonavir) within 7 days from symptom onset.

View Article and Find Full Text PDF

Urinary tract infections are one of the main complications in kidney transplant patients, with a significant impact on graft function and survival. In fact, it is estimated that up to 74% of kidney transplant patients experience at least one episode of UTIs in the first year after transplantation, with an increased risk of graft loss and an increased risk of mortality. Several risk factors have been identified, such as female gender, old age, diabetes mellitus, immunosuppression, pre-transplant UTIs, urinary tract abnormalities, and prolonged dialysis.

View Article and Find Full Text PDF

The triglyceride-glucose (TyG) index is a new alternative insulin resistance (IR) biomarker. The purpose of this study was to assess whether the TyG index can have a prognostic value in patients with acute coronary syndrome (ACS). Moreover, we wanted to compare the TyG index with HOMA index.

View Article and Find Full Text PDF
Article Synopsis
  • Pre-exposure prophylaxis with Tixagevimab/Cilgavimab has effectively reduced COVID-19 risks in immunocompromised patients, but its efficacy is limited against the Kraken variant (XBB.1.5).
  • A study involving kidney transplant patients on this treatment showed only one asymptomatic infection during a six-month follow-up, with no hospitalizations or COVID-related deaths.
  • The results suggest Tixagevimab/Cilgavimab may still be a beneficial preventive option for immunocompromised individuals, underlining the need for further clinical research on this topic.
View Article and Find Full Text PDF